Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von Wedbush 

Immunic Inc. diskutieren

Immunic Inc.

WKN: A2PHD4 / Symbol: IMUX / Name: Immunic / Aktie / Biotechnologie & medizinische Forschung / Small Cap /

0,54 €
1,89 %

Einschätzung Buy
Rendite (%) -37,23 %
Kursziel 5,30
Veränderung
Endet am 16.04.26

Immunic, Inc. (NASDAQ: IMUX) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $6.00 price target on the stock.
Ratings data for IMUX provided by MarketBeat

Einschätzung Buy
Rendite (%) -50,19 %
Kursziel 14,95
Veränderung
Endet am 30.04.26

Immunic, Inc. (NASDAQ: IMUX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $17.00 price target on the stock.
Ratings data for IMUX provided by MarketBeat

Einschätzung Buy
Rendite (%) -48,33 %
Kursziel 8,84
Veränderung
Endet am 01.05.26

Immunic, Inc. (NASDAQ: IMUX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Ratings data for IMUX provided by MarketBeat

Immunic, Inc. (NASDAQ: IMUX) had its "outperform" rating re-affirmed by analysts at William Blair.
Ratings data for IMUX provided by MarketBeat

Einschätzung Buy
Rendite (%) -34,82 %
Kursziel 4,42
Veränderung
Endet am 23.05.26

Immunic, Inc. (NASDAQ: IMUX) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $5.00 price target on the stock, down previously from $6.00.
Ratings data for IMUX provided by MarketBeat

Einschätzung Buy
Rendite (%) -24,86 %
Kursziel 8,89
Veränderung
Endet am 29.05.26

Immunic, Inc. (NASDAQ: IMUX) had its price target lowered by analysts at D. Boral Capital from $17.00 to $10.00. They now have a "buy" rating on the stock.
Ratings data for IMUX provided by MarketBeat

Einschätzung Buy
Rendite (%) -24,86 %
Kursziel 8,76
Veränderung
Endet am 05.06.26

Immunic, Inc. (NASDAQ: IMUX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $10.00 price target on the stock.
Ratings data for IMUX provided by MarketBeat

Einschätzung Buy
Rendite (%) -13,49 %
Kursziel 8,60
Veränderung
Endet am 25.06.26

Immunic, Inc. (NASDAQ: IMUX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $10.00 price target on the stock.
Ratings data for IMUX provided by MarketBeat

Einschätzung Buy
Rendite (%) -34,25 %
Kursziel 8,58
Veränderung
Endet am 08.08.26

Immunic, Inc. (NASDAQ: IMUX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $10.00 price target on the stock.
Ratings data for IMUX provided by MarketBeat

Einschätzung Buy
Rendite (%) -27,95 %
Kursziel 8,52
Veränderung
Endet am 25.09.26

Immunic (NASDAQ:IMUX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $10.00 price target on the stock.
Ratings data for IMUX provided by MarketBeat

Einschätzung Buy
Rendite (%) -31,69 %
Kursziel 8,57
Veränderung
Endet am 26.09.26

Immunic (NASDAQ:IMUX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Ratings data for IMUX provided by MarketBeat

Einschätzung Buy
Rendite (%) -37,68 %
Kursziel 2,56
Veränderung
Endet am 29.09.26

Immunic (NASDAQ:IMUX) is now covered by analysts at Chardan Capital. They set a "buy" rating and a $3.00 price target on the stock.
Ratings data for IMUX provided by MarketBeat

Immunic (NASDAQ:IMUX) was upgraded by analysts at LADENBURG THALM/SH SH to a "strong-buy" rating.
Ratings data for IMUX provided by MarketBeat

Einschätzung Buy
Rendite (%) -12,04 %
Kursziel 2,60
Veränderung
Endet am 07.11.26

Immunic (NASDAQ:IMUX) is now covered by analysts at Roth Capital. They set a "buy" rating and a $3.00 price target on the stock.
Ratings data for IMUX provided by MarketBeat

Einschätzung Buy
Rendite (%) -15,02 %
Kursziel 6,90
Veränderung
Endet am 13.11.26

Immunic (NASDAQ:IMUX) had its price target lowered by analysts at D. Boral Capital from $10.00 to $8.00. They now have a "buy" rating on the stock.
Ratings data for IMUX provided by MarketBeat

Einschätzung Buy
Rendite (%) -17,30 %
Kursziel 6,88
Veränderung
Endet am 14.11.26

Immunic (NASDAQ:IMUX) had its price target lowered by analysts at HC Wainwright from $10.00 to $8.00. They now have a "buy" rating on the stock.
Ratings data for IMUX provided by MarketBeat